Posted by Michael Wonder on 08 Oct 2021
Recursion is granted FDA fast track designation for REC-2282 for the potential treatment of NF2 mutated meningiomas
7 October 2021 - Recursion today announced that the U.S. FDA has granted the company fast track designation for the investigation of REC-2282 for treatment of patients with NF2 mutated meningiomas, including neurofibromatosis type 2 disease related meningiomas.
REC-2282 is a potentially first in class, orally bioavailable, CNS penetrant small molecule HDAC inhibitor being developed for the treatment of NF2 mutated meningiomas.
